{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:43:41Z","timestamp":1761767021049},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Robert Koch-Institut"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                <jats:title>Abstract<\/jats:title>\n              <\/jats:sec><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recent patent losses for antiretroviral drugs (ARV) have led to the debate of cost-saving through the replacement of patented drugs with generic drugs. The split of recommended single-tablet regimens (STR) into their single substance partners is one of the considerations mentioned in said debate. Particularly, generic tenofovir disoproxil\/emtricitabine (TDF\/FTC) is expected to hold untapped cost-saving potential, which may curb increasing overall expenditures for combined antiretroviral therapy (cART) within the statutory health insurance (SHI) of Germany.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data of ARV reimbursed by the SHI were used to describe the trends of defined daily doses (DDD) as well as the revenue within the German ARV market. They were also used to determine the cost-savings of moving to generic drugs. The time period observed was between January 2017 and June 2019. The potential cost-savings were determined with following assumption in mind: the maximum possible use of generic ARV, including 1) the split of STR and replacing all substance partners with generic ones, and 2) replacing patented tenofovir alafenamide\/emtricitabine (TAF\/FTC) with generic TDF\/FTC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Throughout the observation period, the DDD of generic ARV increased nearly five-fold while their revenue increased more than four-fold. Total cost-saving showed a sharp increase over the same period, with generic TDF\/FTC accounting for a share of around 70%. The largest potential cost-saving could have been achieved through replacing patented TAF\/FTC with generic TDF\/FTC, peaking at nearly 10% of total revenue, but showing decreasing trends in general.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The progressive distribution of generic ARV ensured increasing cost-savings<jats:sub>,<\/jats:sub> but consequently curbed the potential cost-savings. Unique price reductions of generic TDF\/FTC have played a pivotal role for these effects. In any case, substituting with generic ARV should not fail to adhere to the treatment guidelines and continue to consider the medical requirements for the treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-021-07390-4","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T06:08:49Z","timestamp":1642054129000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost-savings and potential cost-savings through the distribution of generic antiretroviral drugs within the statutory health insurance market of Germany between January 2017 and June 2019"],"prefix":"10.1186","volume":"22","author":[{"given":"Matth\u00e4us","family":"Lottes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviane","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Prugger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Kollan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"issue":"13","key":"7390_CR1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"FJ Palella","year":"1998","unstructured":"Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853\u201360.","journal-title":"N Engl J Med"},{"issue":"1","key":"7390_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7326\/0003-4819-135-1-200107030-00005","volume":"135","author":"EL Murphy","year":"2001","unstructured":"Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135(1):17\u201326.","journal-title":"Ann Intern Med"},{"issue":"1","key":"7390_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1086\/505147","volume":"194","author":"RP Walensky","year":"2006","unstructured":"Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194(1):11\u20139.","journal-title":"J Infect Dis"},{"key":"7390_CR4","doi-asserted-by":"crossref","unstructured":"Schmidt D, Kollan C, Stoll M, Hamouda O, Bremer V, Kurth T, et al. Everything counts - a method to determine viral suppression among people living with HIV using longitudinal data for the HIV care continuum - results of two large, German, multi-center real-life cohort studies over 20 years (1999\u20132018). BMC Public Health. 2021;21(1):200.","DOI":"10.1186\/s12889-020-10088-7"},{"issue":"9","key":"7390_CR5","doi-asserted-by":"publisher","first-page":"e23946","DOI":"10.1371\/journal.pone.0023946","volume":"6","author":"M Stoll","year":"2011","unstructured":"Stoll M, Kollan C, Bergmann F, Bogner J, Faetkenheuer G, Fritzsche C, et al. Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort. PLoS One. 2011;6(9):e23946.","journal-title":"PLoS One"},{"issue":"5","key":"7390_CR6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10198-012-0425-4","volume":"14","author":"S Mostardt","year":"2013","unstructured":"Mostardt S, Hanhoff N, Wasem J, Goetzenich A, Schewe K, Wolf E, et al. Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGN\u00c4 K3A study. Eur J Health Econ. 2013;14(5):799\u2013808.","journal-title":"Eur J Health Econ"},{"issue":"26","key":"7390_CR7","doi-asserted-by":"publisher","first-page":"e3961","DOI":"10.1097\/MD.0000000000003961","volume":"95","author":"M Treskova","year":"2016","unstructured":"Treskova M, Kuhlmann A, Bogner J, Hower M, Heiken H, Stellbrink H-J, et al. Analysis of contemporary HIV\/AIDS health care costs in Germany: driving factors and distribution across antiretroviral therapy lines. Medicine. 2016;95(26):e3961.","journal-title":"Medicine."},{"key":"7390_CR8","unstructured":"GKV-Spitzenverband. Ausgaben f\u00fcr einzelne Leistungsbereiche der GKV. Ausgaben f\u00fcr Arzneimittel (Apotheken, Versanthandel und Sonstige). 2018. https:\/\/www.gkv-spitzenverband.de\/service\/zahlen_und_grafiken\/gkv_kennzahlen\/gkv_kennzahlen.jsp. Accessed 08 Nov 2021."},{"key":"7390_CR9","unstructured":"Gesundheitsberichterstattung des Bundes. Therapeutische Arzneimittel, die zu Lasten der gesetzlichen Krankenversicherung verordnet wurden. 2018. https:\/\/www.gbe-bund.de\/gbe\/!pkg_olap_tables.prc_set_page?p_uid=gast&p_aid=24419356&p_sprache=D&p_help=2&p_indnr=613&p_ansnr=88826066&p_version=5&D.000=3740. Accessed 08 Nov 2021."},{"key":"7390_CR10","unstructured":"Bundesministerium f\u00fcr Gesundheit. Zahlen und Fakten zur Krankenversicherung. Kennzahlen, Daten, Bekanntmachungen. Informationen. 2021. https:\/\/www.bundesgesundheitsministerium.de\/themen\/krankenversicherung\/zahlen-und-fakten-zur-krankenversicherung\/kennzahlen-daten-bekanntmachungen.html. Accessed 08 Nov 2021."},{"key":"7390_CR11","unstructured":"Bundesanzeiger Verlag GmbH. Gesetz zur St\u00e4rkung des Wettbewerbs in der gesetzlichen Krankenversicherung (GKV-Wettbewerbsst\u00e4rkungsgesetz\u2013GKV-WSG). 2007. https:\/\/www.bgbl.de\/xaver\/bgbl\/start.xav?startbk=Bundesanzeiger_BGBl&start=\/\/*%255B@attr_id=%2527bgbl107s0378.pdf%2527%255D#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl107s0378.pdf%27%5D__1592064265408. Accessed 08 Nov 2021."},{"issue":"8","key":"7390_CR12","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s10198-015-0744-3","volume":"17","author":"KE Fischer","year":"2016","unstructured":"Fischer KE, Stargardt T. The diffusion of generics after patent expiry in Germany. Eur J Health Econ. 2016;17(8):1027\u201340.","journal-title":"Eur J Health Econ"},{"key":"7390_CR13","unstructured":"UNITAID and the Medicines Patent Pool. Patents and licences on antiretrovirals: A Snapshot. 2015. https:\/\/medicinespatentpool.org\/resource-post\/unitaid-mpp-report\/. Accessed 08 Nov 2021."},{"issue":"10097","key":"7390_CR14","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(17)31280-1","volume":"390","author":"R Busse","year":"2017","unstructured":"Busse R, Bl\u00fcmel M, Knieps F, B\u00e4rnighausen T. Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition. Lancet. 2017;390(10097):882\u201397.","journal-title":"Lancet"},{"issue":"3","key":"7390_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.healthpol.2012.12.005","volume":"109","author":"C Henschke","year":"2013","unstructured":"Henschke C, Sundmacher L, Busse R. Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluation. Health Policy. 2013;109(3):263\u20139.","journal-title":"Health Policy"},{"key":"7390_CR16","unstructured":"Gemeinsamer Bundesausschuss. The benefit assessment of medicinal products in accordance with the German social code, book five (SGB V), section 35a. 2020. https:\/\/www.g-ba.de\/english\/benefitassessment\/. Accessed 08 Nov 2021."},{"key":"7390_CR17","unstructured":"Bundesministerium der Justiz und f\u00fcr Verbraucherschutz. Sozialgesetzbuch (SGB) F\u00fcnftes Buch (V). Gesetzliche Krankenversicherung. \u00a7 130a Rabatte der pharmazeutischen Unternehmer. 2020. https:\/\/www.gesetze-im-internet.de\/sgb_5\/__130a.html. Accessed 08 Nov 2021."},{"key":"7390_CR18","unstructured":"Deutsche AIDS-Gesellschaft e.V. Deutsch-\u00d6sterreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion. Version 8. 2019. https:\/\/daignet.de\/site-content\/hiv-leitlinien\/hivleitlinien. Accessed 08 Nov 2021"},{"key":"7390_CR19","unstructured":"Deutsche Aidshilfe. magazin.hiv. HIV-Generika \u2013 same same but different? 2013. https:\/\/magazin.hiv\/2013\/01\/08\/hiv-generika-same-same-but-different\/. Accessed 08 Nov 2021."},{"key":"7390_CR20","doi-asserted-by":"crossref","unstructured":"Schmidt D, Kollan C, Stoll M, Stellenbrink HJ, Plettenberg A, F\u00e4tkenheuer G, et al. From Pills to Patients: Determination of the Number of People Living with HIV who Are Receiving Antiretroviral Therapy, Costs and Potential Cost-savings in Germany. 2015. https:\/\/www.abstractserver.com\/eacsabstractarchive\/. Accessed 04 Jan 2022.","DOI":"10.1186\/s12889-015-1598-4"},{"key":"7390_CR21","unstructured":"European Medicines Agency. First medicine for HIV pre-exposure prophylaxis recommended for approval in the EU. 2016. https:\/\/www.ema.europa.eu\/en\/news\/first-medicine-hiv-pre-exposure-prophylaxis-recommended-approval-eu. Accessed 08 Nov 2021."},{"issue":"Suppl 2","key":"7390_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s15006-018-0656-0","volume":"160","author":"M Stoll","year":"2018","unstructured":"Stoll M. Generic antiretroviral drugs and their potential for cost reduction. MMW Fortschr Med. 2018;160(Suppl 2):37\u20139.","journal-title":"MMW Fortschr Med"},{"key":"7390_CR23","doi-asserted-by":"crossref","unstructured":"Stoll M, Balkin P, Goldbach J, Weber P, Peetroons B, Gokhale SB. Budget Impact Analysis Highlighting the Cost-Saving Potential of Generic Tenofovir Disoproxil Based Antiretroviral Therapy in Comparison with Tenofovir Alafenamide Based Treatment Regimens in the German Healthcare System. Journal of AIDS & Clinical Research. 2017;09(01).","DOI":"10.4172\/2155-6113.1000754"},{"issue":"10","key":"7390_CR24","doi-asserted-by":"publisher","first-page":"776","DOI":"10.7326\/0003-4819-158-10-201305210-00015","volume":"158","author":"G Hirnschall","year":"2013","unstructured":"Hirnschall G, de Joncheere C. Cost-effectiveness of generic antiretroviral therapy. Ann Intern Med. 2013;158(10):776.","journal-title":"Ann Intern Med"},{"key":"7390_CR25","doi-asserted-by":"crossref","unstructured":"Ong KJ, van Hoek AJ, Harris RJ, Figueroa J, Waters L, Chau C, et al. HIV care cost in England: a cross-sectional analysis of antiretroviral treatment and the impact of generic introduction. HIV Med. 2019.","DOI":"10.1111\/hiv.12725"},{"issue":"12","key":"7390_CR26","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1177\/0956462417696215","volume":"28","author":"JA Kieran","year":"2017","unstructured":"Kieran JA, O'Reilly E, O'Dea S, Bergin C, O'Leary A. Generic substitution of antiretrovirals: patients' and health care providers' opinions. Int J STD AIDS. 2017;28(12):1239\u201346.","journal-title":"Int J STD AIDS"},{"issue":"2","key":"7390_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.7326\/0003-4819-158-2-201301150-00002","volume":"158","author":"RP Walensky","year":"2013","unstructured":"Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013;158(2):84\u201392.","journal-title":"Ann Intern Med"},{"issue":"9","key":"7390_CR28","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1586\/14787210.2014.944506","volume":"12","author":"E Van den Eynde","year":"2014","unstructured":"Van den Eynde E, Podzamczer D. Switch strategies in antiretroviral therapy regimens. Expert Rev Anti-Infect Ther. 2014;12(9):1055\u201374.","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"7390_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2147\/PPA.S31385","volume":"6","author":"G Sterrantino","year":"2012","unstructured":"Sterrantino G, Santoro L, Bartolozzi D, Trotta M, Zaccarelli M. Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era. Patient preference and adherence. 2012;6:427\u201333.","journal-title":"Patient preference and adherence"},{"issue":"4","key":"7390_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/phar.1728","volume":"36","author":"S Scott Sutton","year":"2016","unstructured":"Scott Sutton S, Magagnoli J, Hardin JW. Impact of pill burden on adherence, risk of hospitalization, and viral suppression in patients with HIV infection and AIDS receiving antiretroviral therapy. Pharmacotherapy. 2016;36(4):385\u2013401.","journal-title":"Pharmacotherapy."},{"key":"7390_CR31","unstructured":"European Medicines Agency. ATC code. 2021. https:\/\/www.ema.europa.eu\/en\/glossary\/atc-code. Accessed 08 Nov 2021."},{"key":"7390_CR32","unstructured":"World Health Organization. Defined Daily Dose (DDD). Definition and general considerations. 2021. https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/about-ddd. Accessed 08 Nov 2021."},{"issue":"18","key":"7390_CR33","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2146\/ajhp140575","volume":"72","author":"JM Duggan","year":"2015","unstructured":"Duggan JM, Akpanudo B, Shukla V, Gutterson G, Eitniear L, Sahloff EG. Alternative antiretroviral therapy formulations for patients unable to swallow solid oral dosage forms. American J Health-System Pharmacy. 2015;72(18):1555\u201365.","journal-title":"American J Health-System Pharmacy"},{"issue":"10","key":"7390_CR34","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1111\/liv.14155","volume":"39","author":"P Marcellin","year":"2019","unstructured":"Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, et al. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int. 2019;39(10):1868\u201375.","journal-title":"Liver Int"},{"key":"7390_CR35","first-page":"667253","volume":"9","author":"A Maisa","year":"2021","unstructured":"Maisa A, Kollan C. An der Heiden M, van Bommel F, Cornberg M, Mauss S, et al. increasing number of individuals receiving hepatitis B nucleos(t) ide analogs therapy in Germany, 2008-2019. Front. Public Health. 2021;9:667253.","journal-title":"Public Health"},{"issue":"7","key":"7390_CR36","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/jac\/dkw032","volume":"71","author":"C Marzolini","year":"2016","unstructured":"Marzolini C, Gibbons S, Khoo S, Back D. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016;71(7):1755\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"7390_CR37","unstructured":"vfa-patientenportal. Rabattvertr\u00e4ge und ihre Folgen. 2020. https:\/\/www.vfa-patientenportal.de\/arzneimittel\/verordnung-und-erstattung\/rabattvertraege-und-ihre-folgen.html. Accessed 08 Nov 2021."},{"key":"7390_CR38","unstructured":"GKV-Spitzenverand. Rahmenvertr\u00e4ge zur Arzneimittelversorgung. Rahmenvertrag \u00fcber die Arzneimittelversorgung nach \u00a7 129 Absatz 2 SGB V in der Fassung vom 01. April 2020. 2020. https:\/\/www.gkv-spitzenverband.de\/media\/dokumente\/krankenversicherung_1\/arzneimittel\/rahmenvertraege\/apotheken\/Rahmenvertrag_nach_129_Abs.2_SGB_V_vom_01.04.2020_.pdf. Accessed 08 Nov 2021."},{"key":"7390_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.11606\/S1518-8787.2018052000399","volume":"52","author":"JO Costa","year":"2018","unstructured":"Costa JO, Ceccato M, Silveira MR, Bonolo PF, Reis EA, Acurcio FA. Effectiveness of antiretroviral therapy in the single-tablet regimen era. Rev Saude Publica. 2018;52:87.","journal-title":"Rev Saude Publica"},{"key":"7390_CR40","doi-asserted-by":"publisher","first-page":"205031211881691","DOI":"10.1177\/2050312118816919","volume":"6","author":"SN Kapadia","year":"2018","unstructured":"Kapadia SN, Grant RR, German SB, Singh B, Davidow AL, Swaminathan S, et al. HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens. SAGE open medicine. 2018;6:2050312118816919.","journal-title":"SAGE open medicine"},{"issue":"1","key":"7390_CR41","first-page":"44","volume":"40","author":"WR Truong","year":"2015","unstructured":"Truong WR, Schafer JJ, Short WR. Once-daily, single-tablet regimens for the treatment of HIV-1 infection. P & T : a peer-reviewed journal for formulary management. 2015;40(1):44\u201355.","journal-title":"P & T : a peer-reviewed journal for formulary management"},{"issue":"3","key":"7390_CR42","first-page":"168","volume":"14","author":"JM Llibre","year":"2012","unstructured":"Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012;14(3):168\u201378.","journal-title":"AIDS Rev"},{"issue":"1","key":"7390_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/QAI.0000000000000940","volume":"72","author":"D Wohl","year":"2016","unstructured":"Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, et al. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquired Immune Deficiency Syndromes (1999). 2016;72(1):58\u201364.","journal-title":"J Acquired Immune Deficiency Syndromes (1999)"},{"key":"7390_CR44","doi-asserted-by":"crossref","unstructured":"Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, et al. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. Journal of acquired immune deficiency syndromes (1999). 2016;71(5):530\u20137.","DOI":"10.1097\/QAI.0000000000000908"},{"issue":"2","key":"7390_CR45","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/QAI.0000000000001344","volume":"75","author":"F Raffi","year":"2017","unstructured":"Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, et al. Brief report: long-term (96-week) efficacy and safety after switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-infected, Virologically suppressed adults. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2017;75(2):226\u201331.","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"issue":"6","key":"7390_CR46","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2217\/hiv.10.47","volume":"4","author":"JE Lake","year":"2010","unstructured":"Lake JE, Currier JS. Switching antiretroviral therapy to minimize metabolic complications. HIV Ther. 2010;4(6):693\u2013711.","journal-title":"HIV Ther"},{"issue":"Supplement_3","key":"7390_CR47","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.1086\/533418","volume":"197","author":"JJ Eron","year":"2008","unstructured":"Eron JJ. Managing Antiretroviral Therapy: Changing Regimens, Resistance Testing, and the Risks from Structured Treatment Interruptions. J Infect Dis. 2008;197(Supplement_3):S261\u2013S71.","journal-title":"J Infect Dis"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-07390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-021-07390-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-07390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T06:12:22Z","timestamp":1642054342000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-021-07390-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7390"],"URL":"https:\/\/doi.org\/10.1186\/s12913-021-07390-4","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"22 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No administrative permissions were required to access the raw data. Insight Health\u2122 provides the antiretroviral therapy prescription data on a regular basis to the Unit for HIV\/AIDS, STI and Blood-borne Infections at the Robert Koch Institute for research purpose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"\u2018Not applicable\u2019.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ML, VB, CP and DS declare that they have no competing interests. CK is small shareholder in ABBV and JNJ (co) manufacturing the ATC codes J05AE03, J05AE10, J05AG04, J05AG05, J05AR10 and J05AR22.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}